Autres langues Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Temps réel estimé Cboe BZX Autres places de cotation 20:00:01 30/04/2024			Varia. 5j.	Varia. 1 janv.
22,33 ^USD	+1,87 %		+1,09 %	+183,27 %

03/04	JASPER THERAPEUTICS, INC. : Evercore ISI maintient sa recommandation à l'achat	ZM
28/03	JASPER THERAPEUTICS, INC. : RBC Capital Markets réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Jasper Therapeutics : Corporate Presentation April 2024	16/04
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	21/03
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19/03
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19/03
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia	15/03
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	15/03
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/03
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments	04/03
Jasper Therapeutics : Corporate Presentation March 2024	04/03
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference	26/02
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	26/02
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting	23/02
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference	07/02
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise	06/02
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock	06/02
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	06/02
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting	05/02
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Autres langues

Filtres